

**DECISION OF THE EEA JOINT COMMITTEE**  
**No 64/2019**

**of 29 March 2019**

**amending Annex II (Technical regulations, standards, testing and certification) to the  
EEA Agreement**

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (“the EEA Agreement”),  
and in particular Article 98 thereof,

Whereas:

- (1) Regulation (EU) 2018/1718 of the European Parliament and of the Council of 14 November 2018 amending Regulation (EC) No 726/2004 as regards the location of the seat of the European Medicines Agency<sup>1</sup> is to be incorporated into the EEA Agreement.
- (2) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

*Article 1*

The following indent is added in point 15zb (Regulation (EC) No 726/2004 of the European Parliament and of the Council) of Chapter XIII of Annex II to the EEA Agreement:

‘- **32018 R 1718:** Regulation (EU) 2018/1718 of the European Parliament and of the Council of 14 November 2018 (OJ L 291, 16.11.2018, p. 3).’

*Article 2*

The text of Regulation (EU) 2018/1718 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the *Official Journal of the European Union*, shall be authentic.

*Article 3*

This Decision shall enter into force on 30 March 2019, provided that all the notifications under Article 103(1) of the EEA Agreement have been made\*.

*Article 4*

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the *Official Journal of the European Union*.

Done at Brussels, 29 March 2019.

---

<sup>1</sup> OJ L 291, 16.11.2018, p. 3.

\* No constitutional requirements indicated.

*For the EEA Joint Committee  
The President*

*Claude Maerten*

*The Secretaries  
to the EEA Joint Committee*

*Hege M. Hoff*

*Mikołaj Karłowski*

Provisional text